Lista de obras - Angelo Delmonte - Dominio Público Uruguay

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

artículo científico

AVE8062: a new combretastatin derivative vascular disrupting agent.

artículo científico publicado en 2009

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.

artículo científico publicado en 2017

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

artículo científico publicado en 2015

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

artículo científico publicado en 2017

Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver

artículo científico publicado en 2007

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung

artículo científico publicado en 2013

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

artículo científico publicado en 2016

Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.

artículo científico publicado en 2012

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

artículo científico publicado en 2014

Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma

artículo científico publicado en 2011

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

artículo científico publicado en 2016

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

artículo científico publicado en 2015

Molecular features and clinical outcome of lung malignancies in very young people

artículo científico publicado en 2015

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

artículo científico publicado en 2017

Molecule-targeted agents in endometrial cancer.

artículo científico publicado en 2008

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

artículo científico publicado en 2015

Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.

artículo científico publicado en 2011

Percutaneous ultrasound-guided radiofrequency thermal ablation of malignant osteolyses

artículo científico publicado en 2003

Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors

artículo científico publicado en 2013

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

artículo científico publicado en 2014

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

scientific article published on 27 March 2014

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors

artículo científico publicado en 2015

Radiofrequency ablation combined with percutaneous ethanol injection in the treatment of hepatocellular carcinoma and portal vein neoplastic thrombosis

artículo científico publicado en 2004

Safety of Systemic Chemotherapy in a Patient With Mitochondrial Myopathy and Non–Small-Cell Lung Cancer

artículo científico publicado en 2012

Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer

artículo científico publicado en 2010

Scrotal involvement in Madelung disease: clinical, ultrasound and MR findings

artículo científico publicado en 2006

Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.

artículo científico publicado en 2008

Spontaneous rupture of non-parasitic hepatic cyst.

artículo científico publicado en 2006

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options

artículo científico publicado en 2013

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results

artículo científico

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study

artículo científico publicado en 2013

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

artículo científico

Lista de obras de Angelo Delmonte

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

AVE8062: a new combretastatin derivative vascular disrupting agent.

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Molecular features and clinical outcome of lung malignancies in very young people

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Molecule-targeted agents in endometrial cancer.

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.

Percutaneous ultrasound-guided radiofrequency thermal ablation of malignant osteolyses

Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors

Radiofrequency ablation combined with percutaneous ethanol injection in the treatment of hepatocellular carcinoma and portal vein neoplastic thrombosis

Safety of Systemic Chemotherapy in a Patient With Mitochondrial Myopathy and Non–Small-Cell Lung Cancer

Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer

Scrotal involvement in Madelung disease: clinical, ultrasound and MR findings

Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.

Spontaneous rupture of non-parasitic hepatic cyst.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.